Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Ole Maaløes Vej 24, Copenhagen, 7521. 2200, Denmark.
Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
World J Urol. 2024 Sep 14;42(1):523. doi: 10.1007/s00345-024-05234-4.
To investigate the early implementation of combined systematic and targeted (cBx) primary biopsy in prostate cancer diagnosis and define the concordance in Gleason grading (GG) of different biopsy techniques with radical prostatectomy (RP) pathology.
This population-based analysis includes data on all men in Denmark who underwent primary cBx or standalone systematic (sBx) prostate biopsy between 2012 and 2016. Biopsy results were compared to RP pathology if performed within a year. Concordance measurement was estimated using Cohen's Kappa, and the cumulative incidence of cancer-specific death was estimated at 6 years with the Aalen-Johansen estimator.
Concordance between biopsy and RP pathology was 0.53 (95CI: 0.43-0.63), 0.38 (95CI: 0.29-0.48), and 0.16 (95CI: 0.11-0.21) for cBx, targeted biopsy (tBx), and sBx, respectively. For standalone sBx and RP, concordance was 0.29 (95CI: 0.27-0.32). Interrelated GG concordance between tBx and sBx was 0.67 (95CI: 0.62-0.71) in cBx. The proportion of correctly assessed GG based on RP pathology was 54% in both cBx and standalone sBx. Incidence of prostate cancer-specific death was 0% regardless of biopsy technique in GG 1, and 22% (95CI: 11-32), 30% (95CI: 15-44), and 19% (95CI: 7.0-30) in GG 5 for cBx, tBx, or sBx, respectively.
Overall, the cBx strategy demonstrates higher concordance to RP pathology than the standalone sBx. However, cBx exhibits more overgrading of the GG of RP pathology compared to sBx. Ultimately, the classic grading system does not take change in the diagnostic pathway into account, and grading should be altered accordingly to ensure appropriate treatment.
研究前列腺癌诊断中联合系统和靶向(cBx)初次活检的早期实施情况,并确定不同活检技术与根治性前列腺切除术(RP)病理之间在格里森分级(GG)方面的一致性。
本基于人群的分析包括 2012 年至 2016 年间在丹麦接受初次 cBx 或单纯系统(sBx)前列腺活检的所有男性的数据。如果在一年内进行 RP 病理检查,则将活检结果与之进行比较。使用 Cohen 的 Kappa 估计一致性测量值,并使用 Aalen-Johansen 估计器估计 6 年内癌症特异性死亡的累积发生率。
cBx、靶向活检(tBx)和 sBx 的活检与 RP 病理的一致性分别为 0.53(95CI:0.43-0.63)、0.38(95CI:0.29-0.48)和 0.16(95CI:0.11-0.21)。单独的 sBx 和 RP 的一致性为 0.29(95CI:0.27-0.32)。cBx 中 tBx 和 sBx 之间相关的 GG 一致性为 0.67(95CI:0.62-0.71)。基于 RP 病理,cBx 和单独的 sBx 中正确评估 GG 的比例分别为 54%。在 GG1 中,无论活检技术如何,前列腺癌特异性死亡的发生率均为 0%,而在 GG5 中,cBx、tBx 或 sBx 的发生率分别为 22%(95CI:11-32)、30%(95CI:15-44)和 19%(95CI:7.0-30)。
总体而言,cBx 策略与 RP 病理的一致性高于单独的 sBx。然而,cBx 与 sBx 相比,更倾向于对 RP 病理的 GG 进行过度分级。最终,经典分级系统没有考虑诊断途径的变化,应该相应地改变分级,以确保适当的治疗。